Allarity Therapeutics, Inc. announced the closing of a $20 million non-convertible debt financing with Streeterville Capital on March 6, 2026. The proceeds are expected to extend the Company's cash runway into the summer of 2028 and fund completion of the Phase 2 ovarian cancer trial for stenoparib, acceleration toward pivotal trial, FDA approval, and commercialization.
Key takeaways
Closed $20 million non-convertible debt financing with Streeterville Capital on March 6, 2026
Issued two promissory notes: $10,930,000 unsecured and $10,000,000 secured, providing approximately $20 million in net proceeds
Financing extends cash runway into summer of 2028
Proceeds to fund Phase 2 ovarian cancer trial completion, FDA meeting preparation, companion diagnostic strategy, and pivotal development of stenoparib
Stenoparib is a dual PARP and WNT pathway inhibitor in Phase 2 trials for platinum-resistant ovarian cancer patients